BR0316599A - Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncional - Google Patents
Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncionalInfo
- Publication number
- BR0316599A BR0316599A BR0316599-0A BR0316599A BR0316599A BR 0316599 A BR0316599 A BR 0316599A BR 0316599 A BR0316599 A BR 0316599A BR 0316599 A BR0316599 A BR 0316599A
- Authority
- BR
- Brazil
- Prior art keywords
- effector
- lymphoma
- targeting agents
- reagent
- functions linked
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
"AGENTES DE ALVEJAMENTO ANTI-LINFOMA COM FUNçõES EFETORAS E DE AFINIDADE LIGADAS POR UM REAGENTE TRIFUNCIONAL". Um agente medicinal compreendendo um reagente conjugado a um anticorpo anti-linfoma é descrito, bem como um kit contendo o referido agente medicinal, uso do referido agente medicinal, e um método para tratamento de linfomas. O reagente pode compreender um efetor, por exemplo, um agente antitumor ou um marcador diagnóstico, e um ligando de afinidade possibilitando depuração extracorpórea do agente. Os três componentes são ligados por um ligador trifuncional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43301202P | 2002-12-13 | 2002-12-13 | |
SE0203731A SE0203731D0 (sv) | 2002-12-13 | 2002-12-13 | Reagent |
PCT/SE2003/001949 WO2004054615A1 (en) | 2002-12-13 | 2003-12-12 | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0316599A true BR0316599A (pt) | 2005-10-04 |
Family
ID=32599441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316599-0A BR0316599A (pt) | 2002-12-13 | 2003-12-12 | Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncional |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1569690B1 (pt) |
JP (1) | JP2006511532A (pt) |
KR (1) | KR20050086907A (pt) |
AU (1) | AU2003287131B2 (pt) |
BR (1) | BR0316599A (pt) |
CA (1) | CA2509103A1 (pt) |
MX (1) | MXPA05006306A (pt) |
NO (1) | NO20052842L (pt) |
PL (1) | PL377213A1 (pt) |
RU (1) | RU2005122033A (pt) |
WO (1) | WO2004054615A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
NZ547558A (en) * | 2003-11-17 | 2009-06-26 | Genentech Inc | Compositions and methods for the treatment of tumor of hematopoietic origin |
FR2875410B1 (fr) * | 2004-09-23 | 2012-11-16 | Guerbet Sa | Composes de diagnostique pour le ciblage de recpteur a chimiokines |
KR100699278B1 (ko) * | 2005-05-12 | 2007-03-23 | 학교법인 포항공과대학교 | 수화젤레이터로 유용한 바이오틴-아미노산 결합체 및이로부터 제조된 수화젤 |
SG175597A1 (en) | 2007-10-30 | 2011-11-28 | Genentech Inc | Antibody purification by cation exchange chromatography |
AU2009253539B2 (en) | 2008-04-17 | 2014-03-20 | Io Biotech Aps | Indoleamine 2, 3-dioxygenase based immunotherapy |
AU2009274738B2 (en) | 2008-07-23 | 2012-12-13 | Hanmi Science Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
EP3802855A4 (en) * | 2018-05-31 | 2022-03-23 | George Mason Research Foundation, Inc. | ORGANOMETALLIC MARKERS FOR THE DETECTION OF BIOMOLECULES, METHODS FOR THE SYNTHESIS AND METHODS FOR CONJUGATING AN ORGANOMETALLIC LABEL TO A BIOMOLECULE |
WO2022224980A1 (ja) | 2021-04-20 | 2022-10-27 | 日本メジフィジックス株式会社 | 抗cd20抗体の放射性複合体、及び、放射性医薬 |
KR20230119859A (ko) * | 2022-02-08 | 2023-08-16 | 연세대학교 산학협력단 | 신규 이중타겟 융합항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010023288A1 (en) * | 1999-07-07 | 2001-09-20 | Wilbur D. Scott | Trifunctional reagent for conjugation to a biomolecule |
WO2000002050A1 (en) * | 1998-07-07 | 2000-01-13 | Department Of Radiation Oncology, University Of Washington | Trifunctional reagent for conjugation to a biomolecule |
EP2260866A1 (en) * | 1998-08-11 | 2010-12-15 | Biogen-Idec Inc. | Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
KR20030016250A (ko) * | 2000-04-25 | 2003-02-26 | 아이덱 파마슈티칼즈 코포레이션 | 중추신경계 림프종 치료용 리툭시맵의 초내 투여 |
-
2003
- 2003-12-12 BR BR0316599-0A patent/BR0316599A/pt not_active IP Right Cessation
- 2003-12-12 CA CA002509103A patent/CA2509103A1/en not_active Abandoned
- 2003-12-12 JP JP2004560221A patent/JP2006511532A/ja active Pending
- 2003-12-12 WO PCT/SE2003/001949 patent/WO2004054615A1/en active Application Filing
- 2003-12-12 MX MXPA05006306A patent/MXPA05006306A/es unknown
- 2003-12-12 KR KR1020057010811A patent/KR20050086907A/ko not_active Application Discontinuation
- 2003-12-12 PL PL377213A patent/PL377213A1/pl not_active IP Right Cessation
- 2003-12-12 EP EP03781200A patent/EP1569690B1/en not_active Expired - Lifetime
- 2003-12-12 AU AU2003287131A patent/AU2003287131B2/en not_active Ceased
- 2003-12-12 RU RU2005122033/15A patent/RU2005122033A/ru not_active Application Discontinuation
-
2005
- 2005-06-13 NO NO20052842A patent/NO20052842L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1569690B1 (en) | 2011-07-27 |
WO2004054615A1 (en) | 2004-07-01 |
AU2003287131B2 (en) | 2008-07-24 |
CA2509103A1 (en) | 2004-07-01 |
AU2003287131A1 (en) | 2004-07-09 |
RU2005122033A (ru) | 2006-01-27 |
EP1569690A1 (en) | 2005-09-07 |
MXPA05006306A (es) | 2005-09-21 |
KR20050086907A (ko) | 2005-08-30 |
NO20052842L (no) | 2005-09-12 |
PL377213A1 (pl) | 2006-01-23 |
NO20052842D0 (no) | 2005-06-13 |
JP2006511532A (ja) | 2006-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0316599A (pt) | Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncional | |
BRPI0111220B8 (pt) | conjugados de fármacos com etilenodicisteína (ec) | |
DE60020529D1 (de) | Antikörper zur krebsbehandlung und -diagnose | |
BR0015992A (pt) | Compostos, utilização dos mesmos, e, associações terapêuticas | |
UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
CR8428A (es) | Agente endoparasiticidas para la administracion topica | |
BRPI0412975A (pt) | espuma penetrante para uso farmacêutico | |
BR0111667A (pt) | Novos compostos | |
DE69942578D1 (de) | Bifunktionelle moleküle sowie darauf basierende therapien. | |
BR0206985A (pt) | Anticorpos modificados e métodos de uso | |
ECSP099387A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
BR0211550A (pt) | Derivados de triazolil-imidazopiridina e das triazolilpurinas úteis como ligandos do receptor a2a da adenosina, e seu uso como medicamentos | |
BRPI0416928A (pt) | desenvolvimento de derivados biologicamente ativos de azul de metileno | |
BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
BRPI0414858A (pt) | métodos para preparação de corpos de óleo compreendendo ingredientes ativos | |
TR199800443T1 (xx) | Hidroliz y�kseltici taksan hidrofobik t�revleri. | |
TR200201245T2 (tr) | Kanser tedavisi için onkolitik kombinasyonlar. | |
ATE188873T1 (de) | Tris-platin-komplexe | |
ME00624B (me) | Nova primjena docetaksela za liječenje hepatoma | |
BR0314716A (pt) | Anticorpos de subunidade alfa de lfa-1 e métodos de uso | |
SE0203731D0 (sv) | Reagent | |
BRPI0513856A (pt) | uso de um composto peptìdico | |
BR0111669A (pt) | Novos compostos | |
BR0111726A (pt) | Derivados de biotina | |
DE69612056D1 (de) | Terpenderivate (sarcodictyine) als antikrebsmittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S). |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 51/10 (2006.01), A61K 47/60 (2017.01), A61K 4 |